Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004183 · ClinicalTrials.gov registry record · Phase 2
Capecitabine in Treating Patients With Malignant Mesothelioma
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00004183 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 27 participants.
The verdict
NCT00004183, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have malignant mesothelioma.
Interventions
- DRUG capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2000-11 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004183
The ClinicalTrials.gov registry entry for NCT00004183 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which capecitabine is the first listed.
NCT00004183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004183 about?
NCT00004183 is a clinical study titled "Capecitabine in Treating Patients With Malignant Mesothelioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have malignant mesothelioma.
What is the current status of trial NCT00004183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2000-11. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00004183?
The interventions under investigation include: capecitabine (DRUG).
Who is sponsoring clinical trial NCT00004183?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.